The appeal of porphyrins lies in their photophysics. These conjugated macrocycles, built around 18 π electrons, absorb light strongly across the ultraviolet and visible ranges and can act as photosensitizers. When illuminated, a photosensitizer is excited to a higher energy state and transfers either energy or electrons to nearby oxygen, generating reactive oxygen species such as singlet oxygen and superoxide anions. These reactive species attack bacterial membranes, proteins, and nucleic acids simultaneously. Because the damage is multi-site rather than targeted at a single molecule, the standard resistance strategies that defeat antibiotics are largely ineffective. Photothermal therapy offers a complementary route, using porphyrins to convert light into local heat that destroys cells, while sonodynamic therapy achieves similar chemistry using ultrasound instead of light, reaching tissues that light cannot penetrate.

Free porphyrin molecules, however, have a serious flaw: their flat aromatic rings stack together through strong π interactions, causing aggregation that quenches their photosensitizing ability and limits solubility. The solution, the review explains, is to lock porphyrins into porous frameworks where they are held apart, ordered, and functional. The authors classify these materials into four families defined by their bonding. Porphyrin-based metal–organic frameworks, or PMOFs, link porphyrin ligands such as TCPP to metal ions or clusters through coordination bonds, yielding crystalline networks with large surface areas and tunable pores. Porphyrin-based covalent organic frameworks, PCOFs, connect purely organic building blocks through reversible covalent bonds, typically imine or boronate linkages, producing robust, ordered channels. Hydrogen-bonded organic frameworks, PHOFs, assemble under mild conditions through weaker, reversible interactions, while amorphous porphyrin-based porous polymers, APPPs, sacrifice crystallinity for simplicity, scalability, and extremely high porphyrin loading.

Each family brings distinct advantages and trade-offs. PMOFs prevent photosensitizer aggregation, facilitate mass transport, and embed intrinsic metal functionality, but their stability depends heavily on the metal–ligand combination. Zirconium-based PMOFs are prized for their strong coordination and resistance to degradation, while copper and iron variants display peroxidase-like activity that converts hydrogen peroxide into toxic hydroxyl radicals. Silver-based frameworks release antibacterial silver ions and boost photocatalysis, scandium nodes suppress electron–hole recombination to raise reactive oxygen yields, and bismuth centers disrupt bacterial redox homeostasis by binding hydrogen sulfide. PCOFs offer high chemical stability and metal-free design, though their photodynamic performance is sensitive to linkage chemistry and stacking. PHOFs are the easiest to assemble but the most fragile in aqueous biological environments, and APPPs, despite their disordered pores, are cheap to make and easy to functionalize.

The sophistication of modern design strategies is striking. Metalation of the porphyrin cavity—inserting zinc, palladium, iron, manganese, or copper into the central ring—can steer the balance between the two photodynamic pathways, favoring either energy transfer to singlet oxygen or electron transfer to radical species. Composite construction goes further: core–shell architectures coat scintillator nanoparticles with porphyrin MOF shells for efficient energy transfer; template growth shapes membranes on cellulose; and metal nanoparticles are grown in situ on framework surfaces by chemical, photo-, or thermal reduction, so that silver or platinum particles work in concert with the porphyrin scaffold. Cascade catalytic systems combine multiple active sites so that one reaction feeds the next, for example converting wound hydrogen peroxide into oxygen, which then fuels photodynamic killing.

The clinical applications described in the review center on the hardest problems in infection medicine. Chronic and diabetic wounds, starved of oxygen and colonized by antibiotic-resistant biofilms, are a prime target. Researchers have shown that the topology of a zirconium porphyrin MOF—how its pores and active sites are arranged—directly determines singlet oxygen output, and that shrinking nanosheets to around 160 nanometers dramatically increases both reactive oxygen production and antibacterial power. One clever platform exploits bacterial iron hunger: a gallium–copper porphyrin MOF releases gallium, which mimics iron, while bacteria surrender their own iron to the porphyrin ring, collapsing their nutritional homeostasis in a strategy the authors call iron nutritional immunity therapy. Other systems pair photodynamic and photothermal killing with anti-inflammatory nanozymes that clean up reactive species once the bacteria are gone, promoting tissue repair.

Bone and oral infections demand deeper penetration, and here sonodynamic therapy dominates, since ultrasound can traverse five to ten centimeters of dense cortical bone. Defect-engineered MOFs with homojunction structures have treated methicillin-resistant Staphylococcus aureus osteomyelitis in animal models, preventing bone destruction without surgery. Piezoelectric heterostructures that generate internal electric fields under ultrasound, red-blood-cell-membrane-coated catalysts that neutralize toxins, and FDA-approved bone-targeting drugs grafted onto sonosensitizers that simultaneously inhibit osteoclasts all illustrate how far the field has moved beyond simple light-activated killing. In periodontitis, a zinc porphyrin MOF eradicated Porphyromonas gingivalis with up to 99.9 percent efficiency within five minutes of red-light exposure, then calmed inflammation after being taken up by macrophages.

Remarkably, the applications extend well beyond the clinic. Food preservation films embedding geraniol-loaded MOFs kept cherry tomatoes fresh for twelve days, while thymol-loaded nanofiber membranes protected grapes and strawberries from spoilage. Smart packaging films that release oregano essential oil for up to 140 hours and signal spoilage through pH-responsive fluorescence are already being prototyped. In agriculture, nanopesticides built from copper porphyrin layers encapsulate fungicides within metal–phenolic networks, improving leaf adhesion and bioavailability against plant pathogenic fungi, and magnesium-doped MOFs outperformed commercial fungicide formulations against rice sheath blight. Self-disinfecting textiles woven with porphyrin COFs retained over 80 percent antibacterial activity after sixteen washing cycles, and silver-modified face masks maintained more than 95 percent antiviral efficiency through repeated washing. Wastewater treatment membranes have achieved over 99 percent bacterial killing and simultaneous heavy-metal removal under sunlight, with recyclability across multiple cycles.

The review’s authors are candid about the obstacles that stand between laboratory success and widespread use. Most syntheses still rely on high-temperature, long-duration solvothermal methods that are hard to scale and produce particles prone to aggregation. Long-term toxicity, metabolic fate, and degradation pathways in living organisms remain insufficiently mapped, and the authors call for biocompatible metals such as zinc and calcium, hydrophilic polymer coatings, and physiologically degradable ligands to address these concerns. Antibacterial testing has focused overwhelmingly on two model bacteria, E. coli and S. aureus, while the real microbial world is far more diverse and increasingly resistant. Selectivity is another unsolved problem: current targeting groups improve bacterial affinity but do not truly distinguish pathogens from beneficial microbes. Mechanistic understanding is also limited by the difficulty of imaging reactions at the material–bacteria interface at pore scale.

Even so, the trajectory is unmistakable. By combining the light-harvesting power of porphyrins with the architectural control of modern porous materials, researchers have assembled a platform that can kill bacteria through multiple simultaneous mechanisms, evade the resistance machinery that defeats antibiotics, deliver drugs on demand, and even monitor its own environment. The authors point toward supramolecular assembly, computational design, and greener synthesis as the next frontiers. If those challenges are met, porphyrin-based porous materials could offer what the antibiotic era increasingly cannot: a way to treat the most stubborn infections without breeding new resistance in the process.

Subject of Research: Porphyrin-based porous materials for light-activated antibacterial therapy

Article Title: Porphyrin‐Based Porous Materials for Antibacterial Applications

Article References: Liang, X.-X., Li, X., Xiong, Y., Wang, X., & Yang, Y.-W. (2026). Porphyrin‐Based Porous Materials for Antibacterial Applications. Advanced Science, Article e78159. https://doi.org/10.1002/advs.78159

Image Credits: AI Generated

DOI: 10.1002/advs.78159

Keywords: porphyrin, antibacterial, antimicrobial resistance, metal-organic frameworks, covalent organic frameworks, photodynamic therapy, photothermal therapy, sonodynamic therapy, reactive oxygen species, wound healing, biofilm, wastewater treatment

The engineering logic behind the system addresses two of the most persistent failures of intravesical therapy. The first is physical: bladder tumors are wrapped in a dense extracellular matrix, a scaffolding of collagen and other proteins that acts like a wall, preventing drugs from penetrating beyond the tumor surface. The second is biological: most instilled agents lack any mechanism to distinguish cancer cells from healthy urothelium, so effective doses are difficult to achieve without collateral toxicity. The new microrobot was designed to breach the wall and find the target simultaneously, using living biology as the delivery chassis.

The biological core of the platform is Hathewaya histolytica, a bacterium that naturally secretes collagenolytic enzymes capable of degrading collagen, the dominant structural protein of the tumor stroma. Rather than fighting this enzymatic activity, the researchers harnessed it. Once the bacteria are instilled into the bladder and reach the tumor, they begin digesting the collagen matrix around and within the lesion. This enzymatic excavation loosens the dense tissue architecture, opening channels through which the attached therapeutic payload can diffuse deep into the tumor mass. In effect, the bacterium acts as a self-propelled demolition crew that prepares the ground for the drugs that follow.

Onto this living scaffold the team grafted synthetic components. Bismuth ferrite nanoparticles were coated onto the bacterial surface, endowing the microrobot with responsiveness to external ultrasound. When ultrasound waves are applied from outside the body, these piezoelectric nanoparticles generate reactive oxygen species, highly reactive molecules that inflict oxidative damage on nearby cancer cells. This sonodynamic mechanism gives clinicians remote, spatially controlled activation of the therapy: the drug payload works where the bacteria deliver it, while the ultrasound-triggered ROS attack can be timed and directed by the treating physician. The nanoparticles also contribute to inducing immunogenic cell death, a form of tumor cell demise that releases antigens and danger signals capable of alerting the immune system.

The third component is DM4, a microtubule inhibitor that disrupts the cytoskeleton of dividing cells. As the bacterial collagenases erode the extracellular matrix, DM4 penetrates the loosened tumor and breaks down intercellular networks, further destabilizing the tumor’s structural integrity. The fourth element is a targeting ligand, neurotensin, which binds to the NTS1 receptor that is overexpressed on bladder cancer cells. This ligand acts as a molecular address label, concentrating the microrobot and its payloads on malignant tissue rather than healthy bladder wall. Together, the four modules perform complementary functions: matrix degradation, ligand-guided targeting, cytoskeletal disruption, and ultrasound-triggered oxidative attack.

The laboratory results reported in the study are striking. In vitro, the HH-B-DM4-NT system produced measurable collagen degradation, disrupted three-dimensional tumor spheroids that mimic the architecture of real tumors, and achieved 90.8 percent cancer cell death. Mechanistic analysis revealed that the treated cells suffered mitochondrial dysfunction, DNA damage, and apoptosis, the controlled self-destruction pathway that marks cells for removal. Importantly, the treatment also stimulated dendritic cell maturation, the process by which the immune system’s sentinel cells learn to present tumor antigens to other immune players, and it shifted macrophages toward the M1, or pro-inflammatory, phenotype. Macrophage polarization is a critical determinant of tumor immunity, because M2-like macrophages tend to suppress immune responses and support tumor growth, while M1-like macrophages attack tumor tissue and recruit other immune cells.

The therapeutic promise carried over into animal models. In an orthotopic mouse model of bladder cancer, in which tumors are established inside the bladder itself rather than implanted under the skin, the combined microrobot therapy achieved 82.4 percent tumor inhibition and significantly prolonged survival compared with control groups. Examination of the treated tumors showed increased infiltration of CD8-positive T cells, the cytotoxic lymphocytes responsible for directly killing cancer cells, along with a favorable shift in the M1-to-M2 macrophage ratio. These findings indicate that the local treatment did more than destroy cells on contact; it helped remodel an immunosuppressive tumor microenvironment into one more capable of sustaining a long-term antitumor immune response.

This immunological dimension may prove to be the platform’s most valuable feature. Nonmuscle-invasive bladder cancer is currently managed with transurethral resection followed by intravesical bacillus Calmette-Guérin therapy in higher-risk patients, an approach that relies on provoking a local immune reaction but fails in a substantial fraction of cases, leaving few options short of radical surgery. A therapy that combines immediate cytotoxicity with immune priming could address both the visible tumor and the reservoir of microscopic disease that seeds recurrence. The authors also point to a practical advantage of the intravesical route: tumor debris and residual material can be physically cleared through urination, a form of natural waste removal unavailable to systemically delivered therapies.

The researchers emphasize that the system consolidates tumor targeting, extracellular matrix disruption, immune activation, and physical clearance into one integrated platform, a design philosophy that contrasts with combination regimens requiring multiple separate agents and administration schedules. By making the bacterium itself the carrier, the platform exploits motility and enzymatic secretion that synthetic carriers cannot replicate, while the nanoparticle coating and ligand conjugation add controllability and specificity that raw bacteria would lack. The synergy between bacterial collagenolysis and drug penetration is particularly notable, because stromal barriers are a recognized cause of treatment failure across many solid tumors, not only those of the bladder.

As with any living biotherapeutic, the path from mouse models to patients will demand rigorous evaluation. The authors caution that additional studies are needed to assess the safety and long-term efficacy of the system, including questions of bacterial containment, off-target collagen degradation, and the durability of the immune response. The work was supported by a grant from the Beijing-Tianjin-Hebei Natural Science Foundation Cooperation Project and the National Natural Science Foundation of China, and it appears in Science Bulletin under the title Active bacteria-delivered nanosystems for multimodal bladder cancer therapy. If those safety questions can be answered favorably, bioactive microrobots of this kind could open a new chapter in the treatment of a cancer that has long resisted conventional intravesical approaches, turning the bladder itself into a stage where engineered living machines fight the tumor on behalf of the immune system.

Subject of Research: Ultrasound-responsive bioactive microrobots for nonmuscle-invasive bladder cancer therapy

Article Title: Bioactive microrobot instillation therapy for bladder cancer

Article References: Bioactive microrobot instillation therapy for bladder cancer. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: bladder cancer, microrobot, nanomedicine, sonodynamic therapy, collagenase, bismuth ferrite, DM4, neurotensin, immunotherapy, reactive oxygen species, tumor microenvironment, intravesical therapy

The therapeutic half of this pairing rests on a simple but powerful physical idea. Ultrasound waves, unlike light, penetrate deeply into tissue, and they can be focused with high spatial precision while remaining non-invasive and biologically safe. When ultrasound interacts with engineered nanomaterials, it triggers a repertoire of effects: cavitation, in which microscopic bubbles oscillate and collapse; acoustic droplet vaporization, in which liquid phase-change droplets flash into gas; localized heating; mechanical forces; and the generation of reactive oxygen species. Each of these mechanisms can be harnessed to rupture cell membranes, enhance drug uptake, release payloads on demand or kill tumor cells outright. Sonodynamic therapy, the most prominent of these approaches, uses low-intensity ultrasound to activate so-called sonosensitizers accumulated at tumor sites, producing reactive oxygen species such as singlet oxygen that attack lipids, proteins and DNA, damage mitochondria and induce programmed cell death.

The review details a diverse toolbox of ultrasound-responsive carriers. Microbubbles and nanobubbles act primarily through inertial or stable cavitation, doubling as contrast agents for ultrasound imaging while generating potent mechanical forces. Inorganic nanomaterials such as titanium dioxide and molybdenum disulfide catalytically generate reactive oxygen species under ultrasound excitation, with stable physicochemical properties that ensure consistent performance. Acoustic-thermal conversion materials, including gold nanorods and carbon-based structures, transform sound energy into heat, enabling precisely controlled localized hyperthermia. Polymeric nanoparticles, built from natural polymers such as albumin, gelatin and chitosan or from synthetic polymers that self-assemble, can be engineered for conditional release, co-delivery of multiple drugs and recognition of tumor markers. At the most sophisticated end sit multifunctional hybrid materials that combine cavitation, thermoacoustic effects and controlled drug release within a single polymer or lipid matrix.

What makes the organoid side of the equation equally transformative is fidelity. Patient-derived tumor organoids are grown by culturing tumor cells from an individual patient within a three-dimensional extracellular matrix, where they self-organize into miniature versions of the original tumor. Unlike conventional two-dimensional cell lines, which undergo genetic drift during passaging and lack stromal context, organoids preserve the genomic landscape, histopathological architecture, cellular heterogeneity and key components of the tumor microenvironment of the parent tumor. Animal models, meanwhile, suffer from interspecies differences and translational limitations. The review traces the field’s history from the isolation of the first human embryonic stem cell line in 1998, through Yoshiki Sasai’s pioneering concept of simulating embryonic development in three dimensions and Hans Clevers’ definition of the organoid, to the derivation of patient-derived tumor organoids from colorectal, breast and pancreatic cancers between 2013 and 2015, and on to today’s era of high-throughput automation, multi-omics integration and artificial intelligence.

The synergy between the two technologies is where the review’s central argument takes shape. Organoids provide a clinically relevant human biological context for evaluating behaviors of ultrasound nanomaterials that flat cultures simply cannot capture: how deeply nanoparticles penetrate a three-dimensional extracellular matrix, how efficiently they target heterogeneous cell populations, and how they modulate an immune microenvironment. Conversely, ultrasound nanotechnology transforms the organoid from a static drug-testing model into a dynamic platform capable of physical intervention and mechanistic investigation. In a three-dimensional environment, the distribution of the acoustic field, cavitation effects and thermal effects differ significantly from those in a two-dimensional plane, meaning that results generated in organoids carry substantially greater clinical predictive value.

Concrete experimental capabilities illustrate the point. By co-incubating organoids with fluorescently labeled or dye-loaded ultrasound-responsive nanomaterials and then applying ultrasound, researchers can use confocal laser scanning microscopy to quantify penetration depth, spatial distribution uniformity and accumulation differences between core and peripheral cells. Cavitation from microbubbles can physically loosen the extracellular matrix and transiently reduce interstitial pressure, and changes in nanoparticle penetration before and after sonication can be measured directly, validating acoustically enhanced delivery. In advanced vascularized organoid models, the entire delivery pathway, from extravasation across endothelial networks to diffusion through tumor parenchyma, can be simulated in vitro. Real-time imaging adds a theranostic dimension: microbubbles serve as excellent ultrasound contrast agents, while phase-change nanodroplets transition from liquid to gas under ultrasonic excitation, generating intense nonlinear signals, and lanthanide-doped materials can function simultaneously as contrast agents for ultrasound, photoacoustic and magnetic resonance imaging.

The platform also opens a window onto therapeutic heterogeneity and resistance, two of the most stubborn problems in oncology. Single-cell sequencing or flow cytometry of treated organoids can identify sensitive and resistant cell clusters, revealing, for example, whether sonodynamic therapy preferentially eliminates highly metabolic proliferating cells while sparing quiescent cancer stem cells. Long-term treatment-relapse experiments, in which multiple rounds of ultrasound-nanotherapy are applied, allow researchers to observe clonal evolution and identify gene and pathway changes associated with acquired resistance. On the immunotherapy front, co-culturing immune cells with patient-derived organoids creates so-called immuno-organoids in which sonodynamic therapy’s induction of immunogenic cell death can be watched directly: dendritic cell maturation, antigen presentation and the activation and tumor-infiltrating capacity of cytotoxic T lymphocytes can all be quantified, providing evidence of an in situ vaccine effect. Ultrasound-responsive materials can further remodel the immune microenvironment by depleting regulatory T cells, reprogramming tumor-associated macrophages and disrupting physical barriers to enhance T cell infiltration, converting immunologically cold tumors into hot ones.

The review catalogs recent exemplars of the underlying nanomaterial science. Tin monosulfide nanoparticles have been developed as highly efficient nano-ultrasound sensitizers for fibroproliferative triple-negative breast cancer, overcoming stromal barriers. A holo-transferrin platform with in-situ-grown manganese dioxide, coupled to the sonosensitizer protoporphyrin, crosses the blood-brain barrier for high-specificity magnetic resonance imaging and sonodynamic therapy of glioblastoma. Functionalized graphene nanoribbons have been used to block ovarian cancer spheroid adhesion and enable sonodynamic ablation. A tumor microenvironment-responsive calcium carbonate-platinum-titanium dioxide nanocomposite combines calcium ion overload with sonodynamic immunotherapy, while a multifunctional hydrogel delivering Prussian blue nanozyme and the sonosensitizer Ce6 achieves combined photothermal and sonodynamic therapy. A porphyrin-based copper sensitizer exploits tumor glutathione to restore sonosensitivity, and an ultrasound-responsive, in-situ-gelling hydrogel nanocomposite normalizes the extracellular matrix while delivering tranilast to potentiate immune checkpoint blockade. In organoid-relevant work, a bimetallic copper nitroprusside nanosystem showed low toxicity toward normal liver organoids but potent antitumor effects in high-grade serous ovarian cancer organoids regardless of platinum resistance, and silver nitroprusside proved biocompatible toward normal mouse organoids while toxic toward patient-derived tumor organoids by altering redox balance.

Technological integration is accelerating on several fronts. Organoid-on-a-chip platforms use microfluidics to replicate organ structure and function, applying fluid shear stress to simulate blood-borne drug delivery and enabling real-time, high-content imaging; one multilayer chip co-culturing mesenchymal stem cells and peripheral blood mononuclear cells successfully predicted immunotherapy responses in hepatocellular carcinoma patients. Artificial intelligence is entering the workflow as well: a convolutional neural network called DenseNet 121 can predict the differentiation of kidney organoids from simple bright-field images non-invasively, and hybrid physics-based and deep-learning frameworks can reproduce tumor organoid morphogenesis across culture conditions. The clinical infrastructure is maturing too. As of September 2023, 159 organoid-related cancer projects were registered on ClinicalTrials.gov, organoid drug sensitivity data have been shown to correlate with patient outcomes in bladder and breast cancer, and in July 2022 the U.S. FDA for the first time approved preclinical data from organoid models to support initiation of a clinical trial. In 2024, Chinese experts published the first consensus on organoid drug sensitivity testing in Theranostics.

The authors are candid about the obstacles standing between this vision and routine practice. Ultrasound attenuation, scattering and focusing behave differently in three-dimensional organoids than in homogeneous solutions, so standardized exposure protocols are needed for reproducibility. Organoid platforms face batch-to-batch variability, a lack of standardized culture protocols, unstable long-term immune co-cultures and an inability to fully recapitulate systemic factors such as vascularization and neural innervation. Organ-on-a-chip materials like polydimethylsiloxane suffer from nonspecific drug adsorption, and scaling laboratory prototypes into industrially manufacturable products remains expensive. Ethical frameworks governing organoid establishment and data ownership, along with construction costs and the two-to-three-week turnaround for organoid generation, also constrain adoption. Yet the trajectory the review sketches is unmistakable: a closed-loop translational cycle running from patient to organoid to personalized treatment optimization and back to clinical decision-making, with artificial intelligence generating automated drug response scores and repeat biopsies spawning fresh organoids whenever resistance emerges. If standardization, automation and interdisciplinary integration continue on their current course, the authors conclude, this convergence could finally deliver on the long-promised vision of testing drugs on a patient’s avatar in vitro before a single dose is given.

Subject of Research: Ultrasound-responsive nanomaterials evaluated in patient-derived tumor organoids for precision cancer therapy

Article Title: Ultrasound-responsive nanomaterials for precision therapy in tumor organoids

Article References: Bai, X., Zhao, H., Zhao, Y., Zhou, W., Pang, L., Cheng, W., Yang, K., & Wu, B. (2026). Ultrasound-responsive nanomaterials for precision therapy in tumor organoids. Holistic Integrative Oncology, 5(1), Article 45. https://doi.org/10.1007/s44178-026-00266-9

Image Credits: AI Generated

DOI: 10.1007/s44178-026-00266-9

Keywords: ultrasound, nanomaterials, tumor organoids, sonodynamic therapy, precision oncology, drug delivery, tumor microenvironment, immunotherapy, organ-on-a-chip, artificial intelligence, personalized medicine, reactive oxygen species

The central problem the researchers set out to solve is a familiar one in oncology. Reactive oxygen species, or ROS, are powerful weapons against tumor cells because they can push cells into apoptosis, the well-known programmed suicide pathway, and into ferroptosis, a more recently discovered death mode driven by iron-dependent destruction of cell membranes. But tumors fight back. Cancer cells maintain an arsenal of antioxidant defenses, most notably high levels of the reducing molecule glutathione, which rapidly scavenges ROS before it can do lethal damage. Therapies that rely on a single death pathway are also vulnerable to resistance, since tumor cells can adapt and evade one route of killing. The team reasoned that attacking both apoptosis and ferroptosis simultaneously, while depleting the tumor’s glutathione shield, could overwhelm these defenses.

Each existing ROS-generating modality carries its own baggage. Chemodynamic therapy depends on endogenous hydrogen peroxide inside tumors, which is often too scarce to sustain ROS production. Photodynamic therapy uses light, but light penetrates only a few millimeters into tissue and oxygen is frequently lacking in tumor cores. Sonodynamic therapy, by contrast, uses ultrasound waves that travel deep into the body noninvasively and with a favorable safety profile, making it a natural partner for treating solid tumors buried far below the surface. The challenge was pairing it with a chemotherapy payload in a vehicle stable enough to circulate in blood yet responsive enough to unload its cargo precisely where it is needed.

PSCT answers that challenge with a covalent design. Rather than physically encapsulating drugs inside a carrier, the researchers chemically linked TCPP to one polymer backbone and CPT to another, creating two amphiphilic building blocks that self-assemble into uniform spherical nanoparticles. The two components are joined through disulfide bonds, chemical links that remain intact in the bloodstream but are cleaved by the abundant glutathione found inside tumor cells. This covalent strategy delivered a TCPP content of 35.8 percent in the polymer conjugate, exceeding the sub-30 percent loading typical of comparable TCPP-based platforms, and it minimized premature drug leakage during circulation. The finished nanoparticles measured about 140 nanometers in diameter with a Zeta potential of minus 28.6 millivolts, and they remained stable in storage and in blood-serum conditions for the durations required for intravenous use.

The release behavior confirmed the design logic. Under physiological conditions at neutral pH, cumulative TCPP leakage was only about 4 percent, indicating the payload stays locked in transit. But when the nanoparticles encountered a glutathione-rich, mildly acidic environment mimicking a tumor cell interior, they disassembled, swelling to roughly 209 nanometers, and released nearly 70 percent of their CPT cargo within about 80 hours. Once released, the two drugs execute a coordinated attack. CPT, a topoisomerase I inhibitor long used against breast, liver, and colorectal cancers, inflicts DNA damage that activates caspase enzymes and drives apoptosis. TCPP, energized by ultrasound, generates singlet oxygen that floods the cell with oxidative stress, depletes glutathione further, and pushes lipids in cell membranes toward peroxidation, the biochemical signature of ferroptosis.

In laboratory experiments with CT26 colorectal cancer cells, the combination proved decisively more lethal than either component alone. PSCT plus ultrasound showed an IC50 value of 1.1 micrograms per milliliter, compared with 5.9 for free CPT, 14.4 for TCPP with ultrasound, and 3.2 for the free drug combination. A Chou-Talalay combination index of 0.89, below the threshold of 1, formally confirmed synergy between the chemotherapy and the sonodynamic arm. Fluorescent probes revealed a surge of intracellular ROS and lipid peroxidation after treatment, and bio-electron microscopy captured the aftermath inside the cells: mitochondria that normally appear as elongated organelles with tidy internal cristae were swollen, vacuolated, and stripped of their cristae, morphological evidence of a direct assault on mitochondrial membranes by accumulated lipid peroxides.

Animal studies then tested whether the platform could find tumors and spare healthy tissue. Fluorescently labeled PSCT injected into tumor-bearing mice accumulated strongly at tumor sites, peaking at 24 hours, while a free dye control spread indiscriminately through the body. Ex vivo analysis showed tumor fluorescence far exceeding that of the heart, liver, spleen, lung, and kidney, confirming passive tumor targeting through the enhanced permeability and retention effect. Hemolysis tests showed rupture of red blood cells below 5 percent at all concentrations, and organ histology plus blood chemistry found no liver or kidney damage at the chosen therapeutic dose of 6 milligrams per kilogram. Pharmacokinetic measurements underscored the benefit of the nanocarrier: peak plasma concentration of CPT rose roughly elevenfold compared with free drug, and the 24-hour exposure area increased from 2.52 to 58.61 milligram-hours per liter.

Therapeutic results in the mouse model were dramatic. With ultrasound applied at 1 megahertz and 1.5 watts per square centimeter for five minutes, six hours after each injection, tumor growth in the PSCT plus ultrasound group slowed to a near standstill, yielding a tumor inhibition rate of 85.19 percent. Temperature monitoring showed tumor heating of only about 1.3 degrees Celsius, well below the threshold for thermal damage, confirming that the effect came from ROS generation rather than hyperthermia. Body weight remained stable throughout treatment, organ staining revealed no pathological changes, and serum markers of liver and kidney function stayed within normal ranges. A 14-day repeat-dose toxicity study reinforced the safety picture, though the authors note that higher-dose repeated administration still warrants evaluation.

To understand why the therapy worked so well, the team turned to RNA sequencing of treated cells. The analysis identified 4,107 differentially expressed genes and revealed enrichment of ferroptosis and apoptosis pathways alongside upstream signaling networks including MAPK, PI3K-Akt, p53, and Ras. Anti-ferroptosis genes such as Gpx4, Slc7a11, and Slc3a2 were downregulated while pro-ferroptosis genes Acsl4 and Trp53 rose, and pro-apoptotic genes including Bax and Casp1 climbed as the anti-apoptotic Bcl2 fell. Computational docking suggested CPT can bind caspase-3 with a favorable binding energy of minus 7.6 kilocalories per mole, a prediction supported by stable 100-nanosecond molecular dynamics simulations, though the authors caution this requires biochemical validation. Western blots and tumor immunofluorescence confirmed the protein-level changes: cleaved caspase-3, the executioner of apoptosis, increased sharply, while GPX4, the enzyme that normally defends membranes against ferroptosis, dropped substantially. Notably, both a ferroptosis inhibitor and a caspase blocker partially rescued cell viability to similar degrees, indicating that neither pathway alone accounts for the killing.

The broader significance of the work lies in its demonstration that tumor resistance can be attacked at the level of cell death programming itself. By coupling a deep-penetrating physical trigger with a tumor-specific chemical trigger, and by forcing cancer cells to run two lethal programs simultaneously, PSCT offers a template for therapies that leave tumor cells no single escape route. The researchers suggest that even if tumor cells develop adaptive defenses against one death pathway, the complementary pathway continues to exert cytotoxic pressure, a strategy that could prove valuable against multidrug-resistant malignancies. While clinical translation will require further optimization of dosing, irradiation timing, and safety testing at higher doses, the study presents a compelling case that reprogramming how tumor cells die, rather than merely how they are damaged, may be the key to treating deep-seated solid tumors with precision and minimal toxicity.

Subject of Research: A glutathione-responsive polymeric nanoplatform combining sonodynamic therapy and chemotherapy that induces dual ferroptosis-apoptosis tumor cell death

Article Title: CPT-TCPP polymeric nanoplatform for sonodynamic-chemotherapy synergistic tumor therapy through ferroptosis-apoptosis dual cell death reprogramming

Article References: Wang, L., Zhang, Z., Liu, Q., Zhang, H., Peng, J., & Wang, D. (2026). CPT-TCPP polymeric nanoplatform for sonodynamic-chemotherapy synergistic tumor therapy through ferroptosis-apoptosis dual cell death reprogramming. Materials Today Bio, 41, Article 103699. https://doi.org/10.1016/j.mtbio.2026.103699

Image Credits: AI Generated

DOI: 10.1016/j.mtbio.2026.103699

Keywords: sonodynamic therapy, chemotherapy, camptothecin, TCPP, ferroptosis, apoptosis, nanoparticles, glutathione-responsive, reactive oxygen species, tumor microenvironment, colorectal cancer, drug delivery

The innovation centers on a class of nanoparticles called sonosensitizers, which convert ultrasound energy into destructive chemistry inside tumors. Sonodynamic therapy has attracted growing interest in oncology because ultrasound penetrates more than ten centimeters into tissue, allowing clinicians to activate the therapeutic effect non-invasively and precisely at the tumor site while sparing surrounding healthy tissue. The new material, designated PMP, consists of a dendritic platinum-manganese alloy cloaked in a polyethylene glycol shell. Its branched architecture, assembled from ultrasmall primary nanoparticles through a one-pot solvothermal synthesis, provides an abundance of catalytic active sites, while the PEG coating shifts the surface charge from positive to mildly negative and stabilizes the particles in blood-like environments.

Characterization revealed a hydrodynamic diameter of roughly 23 nanometers and a crystalline PtMn alloy structure confirmed by X-ray diffraction and high-resolution electron microscopy. Crucially, the nanodendrites proved to be environment-responsive: in the acidic, hydrogen-peroxide-rich conditions that define the tumor microenvironment, they disintegrate into sub-10-nanometer fragments, releasing divalent platinum and manganese ions. Under normal physiological conditions the particles remain stable for days, meaning their therapeutic payload is unleashed only where it is needed. Electron spin resonance spectroscopy and molecular probes confirmed that when exposed to ultrasound at clinically reasonable parameters—1 megahertz, 2.0 watts per square centimeter—the material generates two of the most cytotoxic reactive oxygen species known: singlet oxygen and hydroxyl radicals.

The narrow 2.67-electronvolt bandgap of the alloy proved central to this performance. Under ultrasound irradiation, the material achieves efficient separation of electrons and holes, driving a so-called Type I sonodynamic mechanism in which holes directly oxidize water molecules into hydroxyl radicals while electrons react with water and oxygen to form superoxide intermediates. Because this pathway depends far less on ambient oxygen than conventional sonosensitizers, it remains potent even in the hypoxic cores typical of resistant tumors—a long-standing weakness of oxygen-requiring photodynamic and sonodynamic approaches.

In experiments with MCF-7/DDP cells, a breast cancer line engineered to resist cisplatin, the researchers found that the combination of nanodendrites and ultrasound killed roughly 80 percent of tumor cells at the optimized treatment threshold. Notably, adding free cisplatin to the regimen conferred no additional benefit, indicating that the nanosystem does not simply re-sensitize tumors to the old drug but instead defeats resistance through an entirely independent mechanism. Cellular uptake studies traced this independence to a critical difference in how the nanoparticles enter cells. Rather than relying on the copper and ABC transporter pathways that platinum drugs use—pathways resistant tumors overexpress to pump the drug back out—the nanodendrites enter through clathrin-mediated and caveolae-dependent endocytosis. Blocking these endocytic routes with specific inhibitors sharply reduced intracellular metal accumulation, while blocking drug efflux pumps had no effect, confirming that the particles sidestep the canonical resistance machinery altogether.

Once inside, the released Pt(II) ions penetrate the nucleus and inflict DNA damage, restoring apoptotic signaling by conventional chemistry. The manganese ions, meanwhile, execute a second mission: they react with and deplete glutathione, the cell’s master antioxidant, and inactivate the enzyme glutathione peroxidase 4. With antioxidant defenses stripped away, iron-dependent lipid peroxides accumulate catastrophically in cellular membranes—the defining signature of ferroptosis. Electron microscopy of treated cells showed shrunken, membrane-dense mitochondria with dissolved cristae, and the ferroptosis inhibitor Ferrostatin-1 rescued cell viability from about 16 percent to nearly 73 percent, establishing ferroptosis as a primary death pathway driven directly by manganese-mediated glutathione depletion.

But the killing did not stop there. Transcriptomic sequencing of treated cells revealed more than 3,500 differentially expressed genes, with significant enrichment of apoptosis, ferroptosis, pyroptosis and necroptosis gene sets—a coordinated activation pattern the authors identify as PANoptosis, a recently described form of inflammatory programmed cell death in which multiple death-execution programs fire simultaneously. Microscopy captured membrane blebbing and nuclear fragmentation characteristic of apoptosis, membrane rupture and nuclear dissolution of necroptosis, and the swelling, bubble-like protrusions of pyroptosis. Western blots confirmed the molecular cascade: elevated cleaved caspase-3, suppressed Bcl-2, upregulated RIPK3 and phosphorylated MLKL for necroptosis, and activated NLRP3 inflammasome components including cleaved caspase-1 and the pore-forming N-GSDMD fragment for pyroptosis. Pyroptotic membrane rupture then spilled lactate dehydrogenase and the inflammatory cytokines IL-1β and IL-18 into the extracellular space, amplifying the alarm signal to neighboring immune cells.

Safety and biodistribution studies in healthy mice showed no abnormalities in blood counts, organ histology or body weight over two weeks, and ICP-MS tracking demonstrated that platinum and manganese levels in liver and spleen declined substantially by day seven, suggesting efficient clearance without long-term heavy-metal accumulation. In MCF-7/DDP tumor-bearing nude mice, fluorescence imaging showed peak tumor accumulation 12 hours after intravenous injection. When treatment began, the results were striking: all saline-treated control mice died within 22 days, and cisplatin monotherapy barely extended survival, confirming robust resistance in the model. The nanodendrite-plus-ultrasound group achieved a 66.7 percent survival rate at 60 days and a tumor-inhibition rate of 77.8 percent, reducing tumor volume to roughly a quarter of control values. Histological analysis of harvested tumors showed extensive necrosis, maximal DNA damage markers, suppressed proliferation, reduced GPX4, and elevated pyroptotic markers—mirroring the dual ferroptosis and PANoptosis activation observed in cell culture.

The authors emphasize that the ferroptotic and PANoptotic programs feed each other in a positive feedback loop: lipid peroxidation worsens mitochondrial dysfunction, which intensifies PANoptotic signaling, while the collapse of cellular homeostasis during PANoptosis further cripples antioxidant defenses, accelerating ferroptotic progression. This reciprocal crosstalk, they argue, is what allows the therapy to overcome a resistance phenotype that defeats single-mechanism drugs. By combining deep-tissue ultrasound activation, resistance-evading endocytic uptake, metal-ion-triggered redox collapse and multi-pathway cell death in one degradable nanoplatform, the study offers a blueprint for next-generation nanotherapeutics aimed at chemoresistant malignancies. The work was supported by the National Natural Science Foundation of China and Shanghai talent programs, and while clinical translation will require further pharmacological and toxicological validation, the demonstration that a single sonosensitizer can concurrently ignite two synergistic modes of programmed cell death marks a significant conceptual advance in the fight against drug-resistant cancer.

Subject of Research: Ultrasound-activated platinum-manganese nanodendrite sonosensitizers for treating cisplatin-resistant breast cancer via ferroptosis and PANoptosis

Article Title: Engineered nanodendritic sonosensitizers empower sonodynamic-elicited ferroptosis and PANoptosis against platinum-resistant breast cancer

Article References: Chen, J., Shen, Y., Zheng, Y., Kang, J., Wang, X., Diao, X., Chen, Y., & Wu, R. (2026). Engineered nanodendritic sonosensitizers empower sonodynamic-elicited ferroptosis and PANoptosis against platinum-resistant breast cancer. Materials Today Bio, 41, Article 103678. https://doi.org/10.1016/j.mtbio.2026.103678

Image Credits: AI Generated

DOI: 10.1016/j.mtbio.2026.103678

Keywords: sonodynamic therapy, cisplatin resistance, breast cancer, ferroptosis, PANoptosis, nanodendrites, platinum-manganese alloy, reactive oxygen species, ultrasound, glutathione depletion, nanomedicine, pyroptosis

The classical abscopal effect, first described in the mid-twentieth century, refers to the objective regression of a verified, non-irradiated tumor lesion following local radiotherapy delivered elsewhere in the body. The phenomenon appeared to defy conventional radiobiology, since radiation was long regarded as a purely local weapon. With the rise of cancer immunology, however, the explanation shifted from speculation to biology. Local radiation can kill tumor cells in an immunogenic fashion, releasing tumor antigens and danger signals that dendritic cells can capture, process and present to T cells. If those primed T cells then traffic to distant metastases that share the same antigens, they can, in principle, attack tumors that were never touched by the radiation beam.

Yet the authors of the review are careful to draw sharp boundaries between three concepts that have frequently been conflated in the literature. The classical abscopal effect requires radiographic or otherwise objective regression of an untreated distant lesion. An immune abscopal phenomenon, by their definition, denotes a prespecified, reproducible immune change within such a distant lesion that can be attributed to the local intervention, whether or not any shrinkage occurs. Systemic immune reprogramming is a broader, direction-neutral term covering reproducible longitudinal changes in immune composition, clonality, activation, trafficking or suppression measured in peripheral blood or across multiple lesions after local therapy. Crucially, they argue, blood-only changes do not constitute an immune abscopal phenomenon and do not by themselves establish any clinical benefit, a distinction with major consequences for how clinical trials are designed and interpreted.

Behind the strict definitions lies a detailed mechanistic map. Local immunogenic injury, whether delivered by ionizing radiation, high-intensity focused ultrasound, histotripsy or sonodynamic therapy, can initiate a cascade in which dying tumor cells release antigen and adjuvant-like danger signals. Dendritic cells must then cross-present those antigens efficiently to T cells, which must expand in sufficient numbers and acquire the right homing receptors to leave lymph nodes and infiltrate distant tumors. At the distant site, the tumor microenvironment must be permissive: antigen presentation must be intact, and the infiltrating T cells must overcome local immunosuppressive barriers. The review emphasizes that each step in this chain is a potential point of failure, and also a potential point of pharmacological intervention.

The obstacles are as prominent as the opportunities. The authors highlight organ-niche restraint and unfavorable systemic trajectories, including the sobering possibility of treatment-induced distant suppression. Some local therapies may, under certain conditions, expand regulatory T cells, myeloid-derived suppressor cells and M2-polarized macrophages, while elevating immunosuppressive cytokines such as IL-10 and TGF-β. In such cases, the systemic consequence of treating the primary tumor is not immune activation but immune restraint, a favorable abscopal cascade inverted into pathological remodeling. The graphical summary accompanying the review contrasts these two divergent outcomes, underscoring that the direction of systemic immune change after local therapy is not predetermined but shaped by dose, fractionation, modality, timing and the baseline immunological state of the host.

The evidence base underpinning these mechanisms is uneven, and the review does not pretend otherwise. Mechanistic causality, the authors conclude, is supported mainly by preclinical studies, where genetically defined mouse models allow individual steps of the cascade to be tested and manipulated. Human evidence, by contrast, derives from observational studies, correlative analyses embedded in clinical trials, and heterogeneous interventional trials that report occasional distant responses without establishing reproducible abscopal efficacy. Spontaneous regression, concurrent systemic therapy, tumor heterogeneity and measurement artifacts all conspire to make isolated case reports difficult to interpret. The era of immune checkpoint inhibitors has further complicated the picture, because radiation combined with PD-1 or CTLA-4 blockade can produce dramatic distant responses in some patients while failing entirely in others, and disentangling the specific contribution of the local therapy from that of the drug is analytically demanding.

To bring order to this contested terrain, the authors propose a Grade A/B/C framework for classifying claimed abscopal events, along with a five-domain modality comparison, a tiered monitoring strategy and an investigational adaptive loop. All of these tools, they stress, require prospective validation before they can be considered standard. The grading scheme is designed to force investigators to document the untreated lesion before treatment, apply established radiographic and metabolic response criteria, and exclude confounders systematically. The tiered monitoring strategy integrates four assessment pillars: imaging of distant lesions, peripheral immune readouts, profiling of the distant tumor microenvironment where tissue can be obtained, and rigorous exclusion of alternative explanations. Only when all pillars align can a distant response be credibly attributed to the local intervention and its immunological consequences.

The therapeutic implications of this framework are considerable. If the abscopal cascade can be engineered, local therapy could be repositioned from a cytotoxic procedure into a personalized, in situ cancer vaccine. Radiation might be scheduled to coincide with checkpoint blockade at the moment of maximal antigen release. Ultrasound-based modalities such as histotripsy, which mechanically disrupts tissue, and sonodynamic therapy, which generates immune-stimulating tumor debris, might be tuned to maximize immunogenic cell death while minimizing the induction of suppressive myeloid populations. Biomarkers of distant-tumor permissiveness, drawn from biopsy profiling and longitudinal blood immune monitoring, could identify which patients are likely to mount productive systemic responses and which are likely to require additional immunomodulation to overcome organ-niche restraint.

The review also carries a pointed message about clinical trial design. Because blood-only immune changes are insufficient evidence of benefit, trials claiming abscopal efficacy must build in prespecified imaging endpoints for untreated lesions and, where feasible, paired biopsies of distant metastases. Adaptive designs that modify radiation dosing or immunotherapy sequencing based on early immune readouts could accelerate optimization, but only if the endpoints are trustworthy. The authors’ insistence on separating established response criteria from their proposed, still-unvalidated grading system is a deliberate act of epistemic discipline, intended to prevent premature clinical enthusiasm from outrunning the evidence.

For a phenomenon once dismissed as a rare biological fluke, the abscopal effect has come a long way, and this review consolidates its journey from anecdote to mechanism to design principle. The field now possesses a coherent mechanistic architecture linking local immunogenic injury to distant tumor control, a sober account of the suppressive forces that can derail it, and a set of proposed standards for proving that a distant response is what it claims to be. What remains missing is prospective human validation, and that gap now defines the research agenda. If the proposed framework withstands testing, the dream of treating cancer locally while curing it systemically may move from case-report folklore into the mainstream of immunotherapy engineering. Until then, the review stands as both a synthesis and a challenge: the abscopal effect must be earned, definition by definition, experiment by experiment, before it can be prescribed.

Subject of Research: Mechanisms of the abscopal effect and systemic immune reprogramming induced by local cancer therapies

Article Title: The abscopal effect and systemic immune reprogramming: from phenomenon to therapeutic design

Article References: Hong, Z., Huang, Z., Feng, A., Zhao, F., Kuang, J., Lei, Z., Sha, Y., Shao, J., Barui, A. K., Mall, R., Zhao, J., Yang, B., Zhou, Y., Chen, D., & Yuan, Q. (2026). The abscopal effect and systemic immune reprogramming: from phenomenon to therapeutic design. Molecular Cancer. https://doi.org/10.1186/s12943-026-02794-4

Image Credits: AI Generated

DOI: 10.1186/s12943-026-02794-4

Keywords: abscopal effect, radiotherapy, cancer immunotherapy, immune reprogramming, dendritic cells, T cells, checkpoint inhibitors, histotripsy, sonodynamic therapy, tumor microenvironment, TGF-beta, clinical trial design